E-book
The power of using integrated data to understand drug performance
These real-world examples show how integrated data can help you improve medication adherence, track patient journeys, evaluate total cost of care and more.
Dig deeper into the evolving role of real-world evidence
Clinicogenomics linked data advances research
Clinicogenomics data can fuel all stages of development.
Four steps to an enterprise data strategy
Maximize data investments.
Is Your Real-World Data Research Ready?
Go behind the scenes of real-world data.
Insights
The 11 things life sciences leaders need to know
We identified 11 trends worth watching.
An interview with Sheenu Kachru on trends in the life sciences
This interview is part of the "Let's talk" conversation series.
How race and ethnicity data can bridge the health equity gap
The life sciences industry needs robust real-world data. For that data to reflect real-world populations, you need race and ethnicity data.
Let's Talk: Conversations from Optum Life Sciences
Discover what’s on the minds of innovative life science leaders with thought -provoking insights and discussions.
Solve contract challenges for gene therapies
Gene therapies have the potential to be transformative, but there are hurdles to overcome for value-based contracts to become widespread.
Getting ahead of the mental health crisis
See how leaders are advancing data strategies, screenings and exploring ways to connect consumers to mental health support.
How VBC can work for manufacturers
Value-based contracts can present challenges that must be overcome to bring gene therapies to market.
PMSA Webinar: Avoiding common RWD pitfalls
Optum experts give a snapshot of commonly encountered pitfalls when using RWD and recommendations to help avoid them in this PMSA webinar.
4 ways small and emerging biopharma can harness RWD now
Small and emerging biopharma companies are already having an impact on the industry. Learn how RWD can enhance your ability to innovate.
Accelerate drug development with clinicogenomic RWE
Optum, Novartis and GuardantINFORM experts discuss the ever-increasing importance of clinicogenomic data during this Endpoints News webinar.
Watch: OLS Data Leaders at STAT Summit
Break down common missteps when using RWD and create practical strategies to overcome them.
Sleep treatment across the ages
Combining real-world data and primary research helps us better understand insomnia.
Optum Dynamic Assessment of Pregnancies and Infants
Assess the impact of medication use during pregnancy and the impact on infant health.
Demonstrating product value with integrated data
A special webinar hosted by MM&M demonstrates how integrated EHR and claims data offers a new foundation for demonstrating product value.
Optum, FDA collaborate on vaccine and biologic research
FDA reaches agreement with life sciences segment of Optum to provide data and expertise to evaluate and research biologics and vaccines.
Real-world data fills rare disease data gaps
Data removes the barriers to understanding rare disease.
Evolving clinical trials from paper to digital
Accelerate research through a digitized model.
Dynamic Assessment Of Pregnancies And Infants
We help answer questions about maternal and infant health.
The unifying power of integrated data
Read how the integration of EHR and claims data can change what we can collectively learn about outcomes.
Modernizing clinical trials with EHRs
Discover how Optum and three provider organizations leveraged EHR systems to modernize a clinical trial aimed at diabetes treatment.
Reflections on PCMA's recent Annual Meeting
Total cost of care and value-based arrangements between manufacturers and payers is top of mind of HEOR and Medical Affairs leaders.
When ‘Is it safe for me?’ changes to ‘Is it safe for us?’
Studying the impact of treatments on pregnancy and infants can help patients, providers and pharmaceutical companies make key decisions.
Monitoring COVID-19 vaccine safety
Discover insights from Dr. John Seeger’s recent participation at the Duke-Margolis Thirteenth Annual Sentinel Initiative Public Workshop.
New Data Dimensions In Life Sciences Research
Expanded research methods can address cost at the root level.
Curious case of costly complications
How can analytics help tell your cost and outcomes story?
Clinicogenomics: The next big leap in real-world data
Optum clinical genomics is positioned to shape a new generation of evidence that accelerates understanding of disease.
Realizing the full potential of clinicogenomics
Join Optum genomics experts as they discuss the progress being made to develop datasets that will aid in drug discovery and development.
The Curious Case of the Costly Complication
Optum helps a client prove product effectiveness
Real-world data centralized teams
Expanding the use of RWD requires expertise and leadership.
Four steps to a RWD enterprise strategy
Lou Brooks, SVP, Real-World Data and Analytics at Optum
Real Talk on Real-World Evidence: Practical Applications in 2021
Virtual fireside chat with Advisory Board and Optum Life Sciences leaders explores the expanded use and next wave of RWE applications
Pinpoint asthma, COPD and ACOS with EHR data
Optum study highlights clinical clues in asthma and COPD.
Reconcile your RWD expectations to maximize your investment
Understand how routine clinical practice impacts information captured in real-world data (RWD).
Case study: Improving SGLT2i therapy guideline adherence
Article that covers OLS and Boehringer Ingelheim collaboration to increase adherence for patients with diabetes and CVD.
RWD Pitfalls Part 1: Using the right tools to approach RWD
When working with real-world data, learn from the lessons of others to help maximize your own business return.
Clinicogenomics: new, linked data is advancing research
Rich, longitudinal clinicogenomics data can fuel all stages of drug development.
Maximize clinical trial enrollment
Use clinical and claims data to conduct patient finding.
Forward-thinking strategies for 2022
Explore this video series featuring insights for Life Sciences leaders, delivered by experts from across health care.
Clinicogenomics Enable Precision Drug Development | Optum
Pilot Program Lowers Cardiovascular Disease Risk
An innovative program involving patient awareness and provider outreach improves patient use of lipid-lowering therapies.
2023 trends shaping life sciences strategies
Life sciences market experts from Optum and Advisory Board offer their bold predictions and insights in 2023 for the industry.
Building public confidence with health data
See how the FDA and Optum use real-world evidence to monitor the safety and effectiveness of COVID-19 vaccines in our youngest populations.
Informing the FDA BEST Initiative
As a key FDA collaborator, Optum Epidemiology generates reproducible results that inform regulatory decisions for COVID-19 vaccines.
Four steps to an enterprise data strategy
Explore the steps for creating a real-world data strategy that helps life sciences companies to maximize their data investments.
Is Your Real-World Data Research Ready?
Real-world data can help evaluate the effectiveness of medications and therapies, which is why evaluation should be part of the investment.
Preparing for the future of life sciences
Life sciences leaders are thinking differently with data to support novel strategies.
Case study: Identifying patients at risk for a bone break
Optum Life Sciences experts used real-world data to assist in the testing of an algorithm designed to assess for osteoporosis risk.
Break down silos in clinical trial design with RWD and tools
Clinical trial protocol design and feasibility often occur in silos. Learn how to make the overall trial design process more effective.
The 6 trends shaping pharma strategies in 2024
Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain.
Catalyze the use of RWE in the life sciences industry
Discover how using real-world evidence (RWE) in the life sciences industry can help catapult learning and drive impact for your company.
Clinicogenomics: advancing discovery and treatment
Watch Dr. Ashley Brenton, VP, real-world evidence and genomics, Optum Life Sciences, discuss patient journeys and cohort building.
An interview with Jamie Freedman, MD, PhD, and Shalini Mohan, MD
This interview about health equity and clinical trials is part of the "Let's talk" conversation series.
Integrated RWD: the key to accelerating innovation
To maximize the value of clinical innovations, you need dimensional, robust data. Learn about leveraging integrated cost and clinical data.
Interview with Jason Spangler on value assessment frameworks
This interview is part of the "Let's talk" conversation series.
Toward Outcomes-Based Payments
Learn from industry leaders about the push to generate evidence and demonstrate value for health care provider value.
An interview with Chris Boone, PhD on precision medicine
This interview is part of the "Let's talk" conversation series.
Connecting Patients to Clinical Trials in Community Care Settings
Learn how real-world data can increase access beyond traditional research sites.
Natural language processing (NLP) methods for RWD insights
NLP systems allow us to draw insights from billions of unstructured medical notes. Learn more about our NLP methodology in this white paper.
Webinar: Solving trial recruitment challenges with data
Learn from clinical trial leaders how you can address recruitment roadblocks by unlocking real-world data (RWD).
What if pragmatic trials were more practical?
Pragmatic trials look increasingly attractive to researchers, but they’re tough to execute. Learn how to simplify the process.
6 guiding steps for selecting a fit-for-purpose data set
Using RWD that are not fit for purpose can waste time and money. Review 6 simple steps to guide your research towards the right data.
Promoting patient access to gene therapies for rare disorders
Optum Life Sciences experts discuss value-based contracts at the 5th Annual Gene Therapy for Rare Disorders Conference.
What if providers’ clinical data were research-ready?
Providers collect data about patients every day. But what should they be considering — and doing — to put their clinical data to good use?
Novel data collection for a difficult-to-study condition
To build a more complete picture of the patient burden, the Optum HEOR team investigates patients’ experiences with their treatment journey.
Reassess the Inflation Reduction Act with evidence in mind
Cut through the noise of the Inflation Reduction Act of 2022 with key points aimed to help life sciences leaders leverage impactful data.
Life Sciences: Top stakeholder questions to consider
Ask your stakeholders what they need early on. Consider these top questions that patients, providers, payers and regulators are looking to answer.
Missing pieces in the patient journey puzzle
Clinicogenomic data, unstructured data and novel clinical trials solutions can all contribute to completing the view of the patient journey.